omeprazole + dipyridamole + acetylsalicylic acid

A fixed-dose combination drug containing **omeprazole**, **dipyridamole**, and **acetylsalicylic acid** (aspirin). - **Aspirin (acetylsalicylic acid)** is an antiplatelet agent that irreversibly inhibits the enzyme cyclooxygenase-1, thereby reducing the formation of thromboxane A2 and inhibiting platelet aggregation, thus lowering the risk of clot-related cardiovascular events. - **Dipyridamole** inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to increased adenosine available for local antiplatelet effect through potentiation of cyclic AMP; it also inhibits phosphodiesterase, further increasing cyclic nucleotide activity, thereby inhibiting platelet aggregation. - **Omeprazole** is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the hydrogen-potassium ATPase enzyme system at the secretory surface of the gastric parietal cell. It is included to reduce the risk of gastrointestinal toxicity from aspirin. This combination (at least when used as coadministration) may be considered for secondary prevention in cardiovascular or cerebrovascular disease where gastric protection is needed. Pharmacokinetics and pharmacodynamics data confirm that omeprazole does not significantly alter the action of aspirin plus dipyridamole[1][4]. No fixed-dose brand combining all three ingredients is known in major markets, but coadministration is supported by relevant pharmacological studies.

Brand names

Aggrenox

Other names

omeprazole + dipyridamole + acetylsalicylic acid